Glenmark shakes up GLP-1 space with ultra-low-cost semaglutide 

Key Highlights: 

• Glenmark has launched Glipiq in India for type 2 diabetes management, aiming to improve early access to GLP-1 therapy. Approved by CDSCO based on a Phase III study in Indian patients, Glipiq demonstrated favourable efficacy and safety, reinforcing its role in advancing diabetes care 

• Setting a new affordability benchmark, Glipiq’s vial-based formulation offers weekly treatment costs of ~₹325–₹440, significantly lowering barriers to therapy initiation. The vial format, paired with dose-specific syringes, enables physician-guided, flexible dosing, especially useful during early-stage treatment, while also supporting better adherence 

• To balance affordability with convenience, GLIPIQ is also available in pre-filled pens for long-term self-administration, with both formats offered in 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL strengths. Complementing this, Glenmark has introduced its ‘Sankalp’ patient support program to improve initiation and persistence, positioning Glipiq as a structured, accessible solution for sustained diabetes management in India 

Implications: 

By pairing one of the lowest weekly price points in the GLP‑1 segment (₹325–₹440) with a vial‑plus‑pen strategy, Glenmark is clearly targeting early initiation and broad middle‑income uptake in type 2 diabetes rather than just premium urban segments. 
The combination of Phase III India data, flexible vial dosing for physician‑guided starts, pre‑filled pens for maintenance, and the Sankalp support program positions Glipiq as a structured, end‑to‑end GLP‑1 offering that can compete effectively against both multinational and domestic semaglutide players. 

Source: Glenmark | Image: Glenmark